Home

Bank vole related Patents/Patent applications available to the public:

 

Patent/Application number.

Title and Basis for application - see note A

Official inventor(s)

Status - see note B .

Subject.

Applicant

Remarks

PCT Pub. No.: WO9811133

EU Patent: EP0941240

US Patent: 7.101.554

First filed:
11. Sep. 1996 (EU)
9. Sep. 1997 (USA)

"New Picornaviruses, vaccines and diagnostic kits."(EU).

"Picornaviruses, vaccines and diagnostic kits" (USA)

Patent based on this paper : Niklasson et al, 1999.

Bo Niklasson

 Patent granted in EU (EPOline *) and USA (USPTO**)

The sequence of the Ljungan virus is protected, along with its uses in future prophylactic treatments (vaccines) against diabetes, heart disorders and a multitude of other disorders and illnesses.

Two other derived applications have recently been filed to USPTO (7. Jun. 2006 and 29. Jun. 2006)

The applicant in Europe was originally the Swedish company Microtus AB , then Nya Apodemus AB and now Apodemus AB.

In USA the applicant is always the inventor(s); in this case Niklasson.

 

PCT Pub. No. WO03019197 (EU)

EU Patent: EP1432990

US Patent: 7.560.609

First filed:
22. August 2001(EU).
12. August 2004 (USA)

"Diabetic Model" (EU and USA)

Patent application based on these papers: Niklasson et al., 2003a and Freimanis et al., 2003.

Bo Niklasson

Ake Lernmark

Patent granted. Effective as of the 19th November, 2008) EU

Patent granted in USA as of 14th July, 2009

 Seek to protect the use of diabetic bank voles as a new animal model for type 1 diabetes in addition to the use of a general method to facilitate the development of diabetes. The method consists in subjecting any mammal-based animal model to "stress" by keeping it in a cage (excisting animal models will probably fall under the claims too).
Apparently the EU patent covers the use of diabetic bank voles regardless of any previous infection and, second, the use of Ljungan virus infected voles. The US patent appears to solely cover a diabetic model resulting of a combination of "stress" and infection with a Ljungan virus.

The applicant in Europe is the Swedish company Apodemus AB.

In USA the applicant is Niklasson and Lernmark

12 of 14 claims in the EU patent can be directly attributed in full, or in part, to the inventions made by three omitted Danish inventors. The inventions made way prior to any collaboration with the official Swedish inventors are:

1) Bank voles can develop diabetes mellitus as a result of the stress related to captivity.

2) Stress can modulate the proneness to develop diabetes in our bank vole model and, by inference, perhaps in any animal model of diabetes.
See note A.

PCT Pub. No. WO03091386 (EU)

Document number:
20050233311 (USA)

 First filed:
23. April 2002 (EU)
15. June 2005 (USA)

"A new family of Picornaviruses"(EU)

"Family of picornaviruses" (USA)

Patent application was (is) based on this paper : Johansson et al., 2002.

Michael Lindberg

Susanne Johansson

Bo Niklasson

Withdrawn in EU

Pending in USA

Sought (seek, in USA) to protect a part of the Ljungan virus genome.

Both in EU and in USA the applicants is the official inventors, Lindberg, Johansson and Niklasson.  

PCT Pub. No. WO2004073710 (EU)

Document number:
20060018876 (USA)

First filed:
21 February 2003 (EU)
22. August 2005 (USA)

 

 

"Treatment of diseases caused by Ljungan virus by using Pleconaril" (EU)

"Treatment of diseases caused by viral infection" (USA)

It appears for the moment as if this application is not based on a published scientific paper.

Bo Niklasson

Patent granted. (Effective upon publishment in the Patent Gazette on the 2nd July, 2008) (EU)

Patent granted 28th October, 2008 USA

The use of the antiviral medicament PLECONARIL, or a derivate thereof, to treat a multitude of possible Ljungan virus induced illnesses. 14 claims in total (EU).

In the American application there is at present 19 claims where the first 14 in effect is similar to the European application. The last five claims specify that the preferred method to treat this Ljungan infection include treatment with antiserum (based on Ljungan virus antibodies) and Interferon, wherein said interferon includes .alpha..

The applicant in Europe is the Swedish company Apodemus AB.

In USA the applicant is Niklasson.

  

 

Note A (regarding patent base):
The basis for a patent application is, in some instances, a draft of what later is published as a scientific paper. The content of the papers mentioned on this page has been used extensively in both the "Background" and as the "Examples" resulting in the "Claims" of the relevant patent applications. In these patents and applications not one single reference is to be found to the resulting papers. The official merit for the work thereby transfers to the official inventors, and them alone.

If all rightful inventors (= persons who have contributed to one or more claims) are officially mentioned as inventors on a patent/application, conventions are that the application do not need to refer to the draft(s) on which it is build (no matter the number of co-authors). However, should rightful inventors be omitted, the analogy to a corresponding situation in a scientific paper is straightforward: lacking references to the work of others constitute plagiarism and where the responsability rests at the authors of a scientific paper, it rests with the assigned inventors of a patent.

 

Note B (regarding patent searches):
* To perform a search in EU using EPOline: Select "Publication No. "; write the desired PCT Pub. No. and press "Search". After the search is performed, you will see "All documents" to the left and pressing this bottom will disclose the entire correspondence, right from the initial application. The files can be downloaded if wished.

** Following this link will lead to the patent/patent application in United States Patent and Trademark Office (USPTO). Pressing "Home" on the top of the page will enable a search after other patents or patent applications within USPTO.


Last updated the 27th May, 2010